U. S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
x
|
QUARTERLY REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT
OF 1934
|
For the quarterly period
ended August 31, 2012
|
¨
|
TRANSITION
REPORT PURSUANT
TO SECTION 13 OR
15(d) OF THE SECURITIES
EXCHANGE ACT OF
1934
|
For the transition period from ________________
to __________________
Commission File Number: 333-172139
BioPower Operations Corporation
(Exact name of registrant as specified
in its charter)
Nevada
|
|
27-4460232
|
(State or other jurisdiction of
|
|
(IRS Employer
|
incorporation or organization)
|
|
Identification No.)
|
1000 Corporate Drive, Suite 200, Fort
Lauderdale, Florida 33334
(Address of principal executive offices)
Issuer’s telephone number, including area code: +1
954 607 2800
Securities registered pursuant to Section 12(b) of the Act: None.
Securities registered pursuant to Section 12(g) of the Act:
None.
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes
þ
No
¨
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes
þ
No
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
(Do not check if a
smaller reporting company)
|
Smaller reporting company
x
|
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
¨
No
x
Common Stock $0.0001. As of October 22,
2012, 90,680,000 shares of common stock of the issuer were outstanding.
FORWARD LOOKING STATEMENTS AND ASSOCIATED
RISK
Certain statements in this Report, and
the documents incorporated by reference herein, constitute forward looking statements. Such forward looking statements involve
known and unknown risks, uncertainties and other factors which may cause deviations in actual results, performance or achievements
to be materially different from any future results, performance or achievements expressed or implied. Such factors include, but
are not limited to: market and customer acceptance and demand for our products; our ability to market our products; the impact
of competitive products and pricing; the ability to develop and launch new products on a timely basis; the regulatory environment,
including government regulation in the United States; our ability to obtain the requisite regulatory approvals to commercialize
our products; fluctuations in operating results, including spending for development and marketing activities; and other risks
detailed from time-to-time in our filings with the U.S. Securities and Exchange Commission (the “SEC”).
The words "believe, expect, anticipate,
intend and plan" and similar expressions identify predictive statements. These statements are subject to risks and uncertainties
that cannot be known or quantified and, consequently, actual results may differ materially from those expressed or implied by
such predictive statements. Readers are cautioned not to place undue reliance on these predictive statements, which speak only
as of the date they are made.
Unless otherwise noted, all currency figures
in this filing are in U.S. dollars.
Introductory Comment - Use of Terminology
Throughout this Quarterly Report on Form 10-Q, the terms “we,”
“us” and “our” refers to BioPower Operations Corporation and, unless the context indicates otherwise,
our subsidiaries in which we hold 100% of such entities’ outstanding equity securities, including BioPower Corporation (“BioPower
Corporation”), Green Oil Plantations Americas Inc. (“Green Oil”), Green Energy Crops Corporation (“GECC”),
FTZ Exchange LLC. and FTZ Energy Corporation, on a consolidated basis. Unless otherwise indicated, all monetary amounts are reflected
in United States Dollars.
BIOPOWER OPERATIONS CORPORATION
(A Developmental Stage Company)
CONTENTS
|
|
Page
|
PART I.
|
FINANCIAL INFORMATION
|
|
|
|
|
ITEM 1.
|
FINANCIAL STATEMENTS
|
|
|
|
|
|
Consolidated Balance Sheets as of August 31, 2012
(unaudited)
and November 30, 2011
(Audited)
|
5
|
|
|
|
|
Consolidated Statements of Operations and Comprehensive Income (Loss) for the three
and nine months ended August 31, 2012 and August 31, 2011 (unaudited) and from September 13, 2010 (inception) to August 31,
2012
|
6
|
|
|
|
|
Consolidated Statements of Stockholders’ Deficit from September 13, 2010 (inception)
to August 31, 2012 (unaudited)
|
7
|
|
|
|
|
Consolidated Statements of Cash Flows for the nine months ended August 31, 2012
and August 31, 2011and from September 13, 2010 (inception) to August 31, 2012
(unaudited)
|
8
|
|
|
|
|
Notes to Consolidated Financial Statements (unaudited)
|
9-23
|
|
|
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
24
|
|
|
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
33
|
|
|
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
33
|
|
|
|
PART II.
|
OTHER INFORMATION
|
|
|
|
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
34
|
|
|
|
ITEM 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
34
|
|
|
|
ITEM 3.
|
DEFAULT UPON SENIOR SECURITIES
|
34
|
|
|
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
34
|
|
|
|
ITEM 5.
|
OTHER INFORMATION
|
34
|
|
|
|
ITEM 6.
|
EXHIBITS
|
35
|
|
|
|
SIGNATURES
|
|
36
|
|
|
|
Exhibit 31.1
|
Certification Pursuant to Section 302 of the Sarbanes Oxley Act
|
|
|
|
|
Exhibit 32.2
|
Certification Pursuant to Section 906 of the Sarbanes Oxley Act
|
|
PART I
– FINANCIAL INFORMATION
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Financial Statements
August 31, 2012
(Unaudited)
CONTENTS
|
Page(s)
|
|
|
Consolidated Balance Sheets – August 31, 2012 (Unaudited) and November 30, 2011 (Audited)
|
5
|
|
|
Consolidated Statements of Operations and Comprehensive Income (Loss) - Three and Nine Months Ended August 31, 2012 and August 31, 2011 (Unaudited) and from September 13, 2010 (Inception) to August 31, 2012 (Unaudited)
|
6
|
|
|
Consolidated Statement of
Stockholders’ Deficit – From September 13, 2010 (Inception) to August 31, 2012 (Unaudited)
|
7
|
|
|
Consolidated Statements of Cash Flows – Nine Months Ended August 31, 2012 and
2011, and from September 13, 2010 (Inception) to August 31, 2012 (Unaudited)
|
8
|
|
|
Notes to Consolidated Financial Statements (Unaudited)
|
9 - 23
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Balance Sheets
|
|
August 31, 2012
|
|
|
November 30, 2011
|
|
|
|
(Unaudited)
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
4,177
|
|
|
$
|
6,111
|
|
Available-for-sale securities
|
|
|
74,128
|
|
|
|
-
|
|
Prepaid expenses
|
|
|
6,087
|
|
|
|
6,354
|
|
Total Current Assets
|
|
|
84,392
|
|
|
|
12,465
|
|
|
|
|
|
|
|
|
|
|
Equipment - net
|
|
|
20,141
|
|
|
|
24,313
|
|
|
|
|
|
|
|
|
|
|
Other Assets
|
|
|
|
|
|
|
|
|
License - net
|
|
|
242,027
|
|
|
|
245,795
|
|
Security deposit
|
|
|
11,660
|
|
|
|
11,660
|
|
Total Other Assets
|
|
|
253,687
|
|
|
|
257,455
|
|
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$
|
358,220
|
|
|
$
|
294,233
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
378,806
|
|
|
$
|
221,209
|
|
Accounts payable and accrued expenses - related parties
|
|
|
647,222
|
|
|
|
325,251
|
|
Note payable
|
|
|
12,000
|
|
|
|
-
|
|
Notes payable - related parties
|
|
|
42,092
|
|
|
|
-
|
|
Convertible debt - net
|
|
|
120,000
|
|
|
|
3,571
|
|
Total Current Liabilities
|
|
|
1,200,120
|
|
|
|
550,031
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Deficit
|
|
|
|
|
|
|
|
|
Preferred stock, $1 par value; 10,000 and 1,000 shares authorized; 1 and 1 issued and outstanding
|
|
|
1
|
|
|
|
1
|
|
Common stock, $0.0001 par value, 500,000,000 shares authorized; 90,680,000 and 90,280,000 shares issued and outstanding
|
|
|
9,068
|
|
|
|
9,028
|
|
Additional paid-in capital
|
|
|
953,822
|
|
|
|
705,162
|
|
Deficit accumulated during the development stage
|
|
|
(1,666,587
|
)
|
|
|
(969,989
|
)
|
Other comprehensive loss
|
|
|
(138,204
|
)
|
|
|
-
|
|
Total Stockholders' Deficit
|
|
|
(841,900
|
)
|
|
|
(255,798
|
)
|
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders' Deficit
|
|
$
|
358,220
|
|
|
$
|
294,233
|
|
See accompanying notes to consolidated financial
statements
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Statements of Operations
(Unaudited)
|
|
Three Months Ended August 31,
|
|
|
Nine Months Ended August 31,
|
|
|
September 13, 2010 (Inception)
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
to August 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
253,500
|
|
|
$
|
-
|
|
|
$
|
253,500
|
|
|
|
|
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General
and administrative expenses
|
|
|
247,790
|
|
|
|
271,711
|
|
|
|
800,641
|
|
|
|
745,688
|
|
|
|
1,766,580
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
Expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
34,889
|
|
|
|
-
|
|
|
|
119,619
|
|
|
|
-
|
|
|
|
123,669
|
|
Loss on sale of available-for-sale
marketable securities
|
|
|
29,838
|
|
|
|
-
|
|
|
|
29,838
|
|
|
|
-
|
|
|
|
29,838
|
|
Total
Other Expense
|
|
|
64,727
|
|
|
|
-
|
|
|
|
149,457
|
|
|
|
-
|
|
|
|
153,507
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(312,517
|
)
|
|
$
|
(271,711
|
)
|
|
$
|
(696,598
|
)
|
|
$
|
(745,688
|
)
|
|
$
|
(1,666,587
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per common share - basic and diluted
|
|
$
|
(0.00
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares outstanding during the period - basic and diluted
|
|
|
90,631,902
|
|
|
|
90,251,648
|
|
|
|
90,520,545
|
|
|
|
74,111,131
|
|
|
|
74,394,262
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(312,517
|
)
|
|
$
|
(271,711
|
)
|
|
$
|
(696,598
|
)
|
|
$
|
(745,688
|
)
|
|
$
|
(1,666,587
|
)
|
Unrealized
loss on available-for-sale marketable securities
|
|
|
(138,204
|
)
|
|
|
-
|
|
|
|
(138,204
|
)
|
|
|
-
|
|
|
|
(138,204
|
)
|
Comprehensive
loss
|
|
$
|
(450,721
|
)
|
|
$
|
(271,711
|
)
|
|
$
|
(834,802
|
)
|
|
$
|
(745,688
|
)
|
|
$
|
(1,804,791
|
)
|
See accompanying notes to consolidated financial
statements
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Statement of Stockholders'
Deficit
From September 13, 2010 (Inception)
to August 31, 2012
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Deficit
|
|
|
Accumulated Other
|
|
|
Total
|
|
|
|
Preferred Stock, $1 Par Value
|
|
|
Common Stock, $0.0001 Par Value
|
|
|
Paid In
|
|
|
Accumulated during
|
|
|
Comprehensive
|
|
|
Stockholder's
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Development Stage
|
|
|
Loss
|
|
|
Deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock - founders ($0.0001)
|
|
|
-
|
|
|
$
|
-
|
|
|
|
10,000
|
|
|
$
|
1
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss - September 13, 2010 (Inception) to November 30, 2010
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,334
|
)
|
|
|
|
|
|
|
(1,334
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - November 30, 2010
|
|
|
-
|
|
|
|
-
|
|
|
|
10,000
|
|
|
|
1
|
|
|
|
-
|
|
|
|
(1,334
|
)
|
|
|
-
|
|
|
|
(1,333
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancellation of common stock - founders
|
|
|
-
|
|
|
|
-
|
|
|
|
(10,000
|
)
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of preferred stock - founders ($1/share)
|
|
|
1
|
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock - founders ($0.0001/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
32,500,000
|
|
|
|
3,250
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock - related parties ($0.0001/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
12,300,000
|
|
|
|
1,230
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock ($0.0001/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
39,100,000
|
|
|
|
3,910
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,910
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock ($0.25/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
1,200,000
|
|
|
|
120
|
|
|
|
299,880
|
|
|
|
-
|
|
|
|
-
|
|
|
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock ($0.50/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
30,000
|
|
|
|
3
|
|
|
|
14,997
|
|
|
|
-
|
|
|
|
-
|
|
|
|
15,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock for services rendered ($0.012/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
4,150,000
|
|
|
|
415
|
|
|
|
49,585
|
|
|
|
-
|
|
|
|
-
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Issuance of common stock for license ($0.25/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
1,000,000
|
|
|
|
100
|
|
|
|
249,900
|
|
|
|
-
|
|
|
|
-
|
|
|
|
250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Warrants issued for services rendered
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
60,800
|
|
|
|
-
|
|
|
|
-
|
|
|
|
60,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
Debt discount
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
30,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the year ended November 30, 2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(968,655
|
)
|
|
|
-
|
|
|
|
(968,655
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - November 30, 2011
|
|
|
1
|
|
|
|
1
|
|
|
|
90,280,000
|
|
|
|
9,028
|
|
|
|
705,162
|
|
|
|
(969,989
|
)
|
|
|
-
|
|
|
|
(255,798
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock ($0.25/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
200,000
|
|
|
|
20
|
|
|
|
50,180
|
|
|
|
-
|
|
|
|
-
|
|
|
|
50,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for services rendered ($0.65/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
150,000
|
|
|
|
15
|
|
|
|
97,485
|
|
|
|
-
|
|
|
|
-
|
|
|
|
97,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for services rendered ($0.22/share)
|
|
|
-
|
|
|
|
-
|
|
|
|
50,000
|
|
|
|
5
|
|
|
|
10,995
|
|
|
|
-
|
|
|
|
-
|
|
|
|
11,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
90,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
90,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on available-for-sale marketable securities
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(138,204
|
)
|
|
|
(138,204
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the nine months ended August 31, 2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(696,598
|
)
|
|
|
-
|
|
|
|
(696,598
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - August 31, 2012
|
|
|
1
|
|
|
$
|
1
|
|
|
|
90,680,000
|
|
|
$
|
9,068
|
|
|
$
|
953,822
|
|
|
$
|
(1,666,587
|
)
|
|
$
|
(138,204
|
)
|
|
$
|
(841,900
|
)
|
See accompanying notes to consolidated financial
statements
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)
|
|
Nine Months Ended August 31,
|
|
|
September 13, 2010 (Inception)
|
|
|
|
2012
|
|
|
2011
|
|
|
to August 31, 2012
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(696,598
|
)
|
|
$
|
(745,688
|
)
|
|
$
|
(1,666,587
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of license
|
|
|
3,768
|
|
|
|
2,959
|
|
|
|
7,973
|
|
Depreciation
|
|
|
4,172
|
|
|
|
2,109
|
|
|
|
7,619
|
|
Amortization of debt discount
|
|
|
116,429
|
|
|
|
-
|
|
|
|
120,000
|
|
Stock issued for services rendered
|
|
|
108,500
|
|
|
|
50,000
|
|
|
|
158,500
|
|
Warrants issued for services rendered
|
|
|
-
|
|
|
|
60,800
|
|
|
|
60,800
|
|
Available-for-sale securities received as revenue
|
|
|
(253,500
|
)
|
|
|
-
|
|
|
|
(253,500
|
)
|
Loss on sale of available-for-sale securities
|
|
|
29,838
|
|
|
|
-
|
|
|
|
29,838
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
(Increase)/Decrease in:
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses
|
|
|
267
|
|
|
|
(13,151
|
)
|
|
|
6,087
|
|
Security deposit
|
|
|
-
|
|
|
|
(11,660
|
)
|
|
|
(11,660
|
)
|
Increase/(Decrease) in:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
|
157,597
|
|
|
|
392,269
|
|
|
|
378,806
|
|
Accounts payable and accrued liabilities - related party
|
|
|
321,971
|
|
|
|
-
|
|
|
|
647,222
|
|
Net Cash Provided By (Used In) Operating Activities
|
|
|
(207,556
|
)
|
|
|
(262,362
|
)
|
|
|
(527,076
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from the sale of available-for-sale securities
|
|
|
11,330
|
|
|
|
-
|
|
|
|
11,330
|
|
Purchase of equipment
|
|
|
-
|
|
|
|
(29,294
|
)
|
|
|
(27,760
|
)
|
Net Cash Used in Investing Activities
|
|
|
11,330
|
|
|
|
(29,294
|
)
|
|
|
(16,430
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt
|
|
|
90,000
|
|
|
|
-
|
|
|
|
120,000
|
|
Proceeds from notes payable - related parties
|
|
|
42,092
|
|
|
|
2,954
|
|
|
|
65,973
|
|
Proceeds from notes payable
|
|
|
12,000
|
|
|
|
-
|
|
|
|
12,000
|
|
Repayment of notes payable - related parties
|
|
|
-
|
|
|
|
(23,881
|
)
|
|
|
(23,881
|
)
|
Proceeds from issuance of preferred stock
|
|
|
-
|
|
|
|
1
|
|
|
|
1
|
|
Proceeds from issuance of common stock
|
|
|
50,200
|
|
|
|
323,389
|
|
|
|
373,590
|
|
Net Cash Provided By Financing Activities
|
|
|
194,292
|
|
|
|
302,463
|
|
|
|
547,683
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Increase (Decrease) in Cash
|
|
|
(1,934
|
)
|
|
|
10,807
|
|
|
|
4,177
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash - Beginning of Period
|
|
|
6,111
|
|
|
|
20,124
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash - End of Period
|
|
$
|
4,177
|
|
|
$
|
30,931
|
|
|
$
|
4,177
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTARY CASH FLOW INFORMATION:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Paid During the Period for:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income Taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Interest
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for license
|
|
$
|
-
|
|
|
$
|
250,000
|
|
|
$
|
250,000
|
|
Unrealized loss on available-for-sale securities
|
|
$
|
138,204
|
|
|
$
|
-
|
|
|
$
|
138,204
|
|
Debt discount recorded on convertible debt
|
|
$
|
90,000
|
|
|
$
|
-
|
|
|
$
|
120,000
|
|
Cancellation of common stock - founders
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1
|
|
See accompanying notes to consolidated financial
statements
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Note 1 Basis of Presentation
The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
and the rules and regulations of the United States Securities and Exchange Commission for interim financial information.
The financial information as of November
30, 2011 is derived from audited consolidated financial statements presented in the Company’s Annual Report on Form 10-K
for the year ended November 30, 2011. The unaudited interim consolidated financial statements should be read in conjunction with
the Company’s Annual Report on Form 10-K, which contains the audited consolidated financial statements and notes thereto,
together with the Management’s Discussion and Analysis, for the year ended November 30, 2011.
Certain information or footnote disclosures
normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States
of America have been omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial
reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial
position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting
of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results
for the period ended August 31, 2012, are not necessarily indicative of results for the full fiscal year.
Note 2 Nature of Operations and Summary
of Significant Accounting Policies
BioPower Corporation (“BioPower”
or “the Company”) was incorporated in the State of Florida on September 13, 2010. On January 5, 2011, the Company re-domiciled
to Nevada and formed BioPower Operations Corporation, a Nevada corporation. On January 6, 2011, the shareholders of BioPower Corporation
contributed their shares of BioPower Corporation to BioPower Operations Corporation and BioPower Corporation became a wholly-owned
subsidiary.
The Company intends to grow biomass crops
coupled with processing and/or conversion facilities to produce oils, biofuels, electricity and other biomass products. On June 8, 2012, the Company's Chief Executive Officer contributed 100% of his member interest in FTZ
Exchange, LLC, (“FTZ”) which became a 100% wholly subsidiary to the Company for no consideration. On the date of contribution,
FTZ has a 50-50 joint venture, known as, the Qx Health Exchange (“QX”) and a wholly-owned subsidiary, called FTZ Energy
Exchange Corporation, which intends to launch an energy exchange. FTZ is a licensing company which intends to use its business
know-how to develop multiple distribution channels, known as exchanges, for the sale of various products and services. On the date
of contribution, FTZ had a nominal net book value.
To date, the activities of the Company have been limited
to implementing the business plan and raising capital. The Company is still in the development stage.
The Company’s fiscal year end is
November 30.
Principles of Consolidation
All inter-company accounts and transactions have been eliminated
in consolidation.
Development Stage
The Company's consolidated financial statements
are presented as those of a development stage enterprise. Activities during the development stage primarily include negotiating
distribution agreements and marketing the territory for distribution outlets for the product. The Company, while seeking to implement
its business plan, will look to obtain additional debt and/or equity related funding opportunities. The Company has not generated
any revenues from its planned and principal operations since inception.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Risks and Uncertainties
The Company intends to operate in an industry
that is subject to rapid change. The Company's operations will be subject to significant risk and uncertainties including financial,
operational, technological, regulatory and other risks, including the potential risk of business failure. Also, see Note 3 regarding
going concern matters.
Use of Estimates
The preparation of financial statements
in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period.
Such estimates and assumptions for
the periods ended August 31, 2012 and 2011, and assumptions affect, among others, the following:
|
·
|
estimated fair value of share based payments,
|
|
|
|
|
·
|
estimated carrying value, useful lives and related impairment of equipment and intangible assets; and
|
|
|
|
|
·
|
estimated valuation allowance for deferred tax assets, due to continuing and expected future
losses
|
Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from estimates.
Cash and
Cash Equivalents
The Company considers all highly liquid
instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company had
no cash equivalents at August 31, 2012 and 2011.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Marketable
Securities
(A) Classification
of Securities
At the time of acquisition, a security
is designated as held-to-maturity (“HTM”), available-for-sale or trading (“AFS”), which depends on ability
and intent to hold such security to maturity. Securities classified as trading and AFS are reported at fair value, while securities
classified as HTM are reported at amortized cost.
Any unrealized gains and losses are reported
as other comprehensive income (loss). Realized gains (losses) are computed on a specific identification basis and are recorded
in net capital gains (losses) on investments in the combined consolidated statements of operations.
During 2012, the Company sold 2,436,000
shares of their AFS having a cost basis of $41,168, for proceeds of $11,330, resulting in a loss on sale of AFS of $29,838.
The Company’s cost basis in AFS was as follows:
|
|
Amount
|
|
|
Shares
|
|
AFS Acquired - February 2012
|
|
$
|
253,500
|
|
|
|
15,000,000
|
|
Sales in 2012 - at cost
|
|
|
(41,168
|
)
|
|
|
(2,436,000
|
)
|
Balance - August 31, 2012
|
|
$
|
212,332
|
|
|
|
12,564,000
|
|
The composition of the Company’s
investments at August 31, 2012, classified as current assets, is as follows:
|
|
Cost
|
|
|
Fair Value
|
|
|
Unrealized Loss
|
|
|
|
|
|
|
|
|
|
|
|
Common stocks - public company
|
|
$
|
212,332
|
|
|
$
|
74,128
|
|
|
$
|
138,204
|
|
Total available for sale securities
|
|
$
|
212,332
|
|
|
$
|
74,128
|
|
|
$
|
138,204
|
|
Investment income (loss) for the nine
months ended August 31, 2012 and 2011 is as follows:
|
|
2012
|
|
|
2011
|
|
Gross realized losses from sales of available for sale securities
|
|
|
(29,838
|
)
|
|
|
-
|
|
Net unrealized holding loss
|
|
|
(138,204
|
)
|
|
|
-
|
|
Net investment income (loss)
|
|
$
|
(168,042
|
)
|
|
$
|
-
|
|
The Company has a 100% concentration in one publicly traded
stock.
(B) Other
than Temporary Impairment
The Company reviews its equity investment
portfolio for any unrealized losses that would be deemed other-than-temporary and require the recognition of an impairment loss
in income. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions,
the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investments.
Management also considers the type of security, related-industry and sector performance, as well as published investment ratings
and analyst reports, to evaluate its portfolio. Once a decline in fair value is determined to be other than temporary, an impairment
charge is recorded and a new cost basis in the investment is established. If market, industry, and/or investee conditions deteriorate,
the Company may incur future impairments.
The Company has not recorded any impairment
losses as of August 31, 2012 and 2011, respectively.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Equipment
Equipment is stated at cost, less accumulated
depreciation computed on a straight-line basis over the estimated useful lives. Maintenance and repairs are charged to operations
when incurred. Betterments and renewals are capitalized when deemed material. When equipment is sold or otherwise
disposed of, the asset account and related accumulated depreciation account are relieved, and any gain or loss is included in operations.
Equipment is reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. There were
no impairment charges taken during the periods ended August 31, 2012 and 2011.
Intangible Assets
Identifiable intangible assets with finite
lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of potential impairment exist.
Also see Note 8 regarding license agreement.
Investment in Joint Venture
FTZ has entered into a Joint Venture,
the Qx, with a third party to engage in the business of becoming an independent medical &
health network for hospitals, physicians, outpatient and urgent care centers, dental care, vision care, insurance companies, alternative
medicine, medical tourism, pharmaceutical companies, vendors and patients.
FTZ owns fifty percent of the Qx joint venture and will record its investment on the equity basis of accounting. The Company’s proportionate
share of expenses incurred by the Joint Venture will be charged to the statement of operations and adjusted against the Investment
in Joint Venture. Losses from the Joint Venture are only recognized until the investment in the Joint Venture is reduced to zero.
Losses in excess of the investment must be restored from future profits before the Company can recognize its proportionate share
of profits.
As
of August 31, 2012, the Joint Venture had no activity.
Beneficial Conversion Feature and Debt
Discount
For conventional convertible debt where
the rate of conversion is below market value at the date of the agreement, the Company records a “beneficial conversion feature”
(“BCF”) and related debt discount.
When the Company records a BCF, the relative
fair value of the BCF would be recorded as a debt discount against the face amount of the respective debt instrument. The discount
would be amortized to interest expense over the life of the debt. When a conversion of the underlying debt occurs, a proportionate
share of the unamortized amounts is immediately expensed.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Derivative Liabilities
Fair value accounting requires bifurcation
of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their
fair value for accounting purposes. In determining the appropriate fair value, the Company expects to use the Black-Scholes option-pricing
model. In assessing the convertible debt instruments, management would determine if the convertible debt host instrument is conventional
convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered
conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
Once determined, derivative liabilities
are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded
in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative
instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
Share-based payments
The Company recognizes all forms of share-based
payments, including stock option grants, warrants, and restricted stock grants, at their fair value on the grant date, which are
based on the estimated number of awards that are ultimately expected to vest.
Share
based payments, excluding restricted stock, are valued using a Black-Scholes option pricing model.
Share based payment
awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair
value of the share-based payment, whichever is more readily determinable.
The
grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period
.
If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related
to the termination of service.
When
computing fair value, the Company may consider the following variables:
|
●
|
The risk-free interest rate assumption is based on the U.S.
Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant.
|
|
●
|
The Company has not paid any dividends on common stock since
inception and does not anticipate paying dividends on its common stock in the near future.
|
|
●
|
The expected option
term is computed using the “simplified” method as permitted under the provisions of Staff Accounting Bulletin
(“SAB”) 107. SAB 107’s guidance was extended indefinitely by SAB 110.
|
|
●
|
The expected volatility is based on the historical volatility
of the Company’s common stock, based on the daily quoted closing trading prices.
|
|
●
|
The forfeiture
rate is based on the historical forfeiture rate for unvested stock options.
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Earnings per share
Basic earnings (loss) per share is computed
by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period. Diluted earnings
(loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock
equivalents and potentially dilutive securities outstanding during the period.
Since the Company reflected a net loss
in 2012 and 2011, considering any common stock equivalents, if exercisable, would have been anti-dilutive. A separate computation
of diluted earnings (loss) per share is not presented.
The Company has the following potential
common stock equivalents at August 31, 2012 and 2011:
|
|
August 31, 2012
|
|
|
August 31, 2011
|
|
|
|
|
|
|
|
|
Warrants (1)
|
|
|
-
|
|
|
|
1,000,000
|
|
Convertible debt
|
|
|
480,000
|
|
|
|
-
|
|
Total common stock equivalents
|
|
|
480,000
|
|
|
|
1,000,000
|
|
(1) On January 11, 2012, the 1,000,000 warrants expired unexercised.
Reclassifications
Certain amounts have been reclassified to conform to the current
period presentation. Such reclassifications had no effect on the reported results of operations or cash flows.
On August 9, 2012, Dale Shepherd resigned as President and Chief
Operating Officer. As a result of the resignation, related convertible debt was reclassified from convertible debt - related
party to notes payable for purposes of financial statement presentation. The related debt is currently in default, see note 6 (B).
Recent Accounting Pronouncements
There are no new accounting pronouncements
that are expected to have any material impact on the Company’s consolidated financial statements.
Note 3 Going Concern
As reflected in the accompanying consolidated
financial statements, the Company had a net loss of $696,598 and net cash used in operations of $207,556 for the nine months ended
August 31, 2012; and a working capital deficit of $1,115,728 and a stockholders’ deficit of $841,900 at August 31, 2012.
These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The ability of the Company to continue
as a going concern is dependent on Management's plans, which include potential asset acquisitions, mergers or business combinations
with other entities, further implementation of its business plan and continuing to raise funds through debt or equity financings.
The Company will likely rely upon related party debt or equity financing in order to ensure the continuing existence of the business.
The accompanying consolidated financial
statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded
assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
Note 4 Equipment
At August 31, 2012 and November 30, 2011,
equipment consists of the following:
|
|
2012
|
|
|
2011
|
|
|
Estimated Useful Life
|
|
|
|
|
|
|
|
|
|
Computer Equipment
|
|
$
|
27,760
|
|
|
$
|
27,760
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
Less: Accumulated depreciation
|
|
|
(7,619
|
)
|
|
|
(3,447
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment, net
|
|
$
|
20,141
|
|
|
$
|
24,313
|
|
|
|
Note 5 Notes Payable – Related
Parties
|
(A)
|
Period Ended November 30, 2010
|
During November 2010, the Company’s
Chief Executive Officer advanced $10,927. The loan bears interest at 4%, is unsecured and due on demand.
During November 2010, a Company Director
advanced $10,000. The loan bears interest at 4%, is unsecured and due on demand.
|
(B)
|
Year Ended November 30, 2011
|
During December 2010, a Company Director
advanced $506. The loan bears interest at 4%, is unsecured and due on demand.
During January 2011, the Company’s
Chief Executive Officer advanced $832. The loan bears interest at 4%, is unsecured and due on demand.
During January 2011, a Company Director
advanced $631. The loan bears interest at 4%, is unsecured and due on demand.
During February 2011, a Company Director
advanced $985. The loan bears interest at 4%, is unsecured and due on demand.
During May 2011, the Company repaid all
related party advances totaling $23,881.
As of November 30, 2011, the Company owed
$385 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
|
(C)
|
Nine Months Ended August 31, 2012
|
During February 2012, the Company’s
Chief Executive Officer advanced $2,500. The loan bears interest at 4%, is unsecured and due on demand.
During March 2012, the Company’s
Chief Executive Officer advanced $17,000. The loan bears interest at 4%, is unsecured and due on demand.
During April 2012, the
Company’s Chief Executive Officer advanced $9,000. The loan bears interest at 4%, is unsecured and due on demand.
During June 2012, the Company’s
Chief Executive Officer advanced $1,592. The loan is non-interest bearing, unsecured and due on demand.
During July 2012, the Company’s
Chief Executive Officer advanced $12,000. The loan bears interest at 4%, is unsecured and due on demand.
As of August 31, 2012, the Company owes
$924 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
Note 6 Notes Payable –
and Convertible Debt
(A) Year Ended November 30, 2011
During October 2011, a third party investor
advanced $25,000. The loan bears interest at 4%, is unsecured and due on demand. The lender may convert the loan into 100,000 restricted
shares of the Company at $0.25 per share. The Company has determined that this is conventional convertible debt, with a BCF. See
Note 6(C).
During November 2011, a third party investor
advanced $5,000. The loan bears interest at 4%, is unsecured and due on demand. The lender may convert the loan into 20,000 restricted
shares of the Company at $0.25 per share. The Company has determined that this is conventional convertible debt, with a BCF. See
Note 6(C).
As of November 30, 2011, the Company owed
$94 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
(B) Nine Months Ended August 31, 2012
During December 2011 and January 2012,
third party investors advanced $40,000. The loan bears interest at 4%, is unsecured and due on demand. The lender may convert the
loan into 160,000 restricted shares of the Company at $0.25 per share. The Company has determined that this is conventional convertible
debt, with a BCF. See Note 6(C).
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
During April 2012 and May 2012, a third
party investor advanced $50,000. The loan bears interest at 4%, is unsecured and due on demand. The lender may convert the loan
into 200,000 restricted shares of the Company at $0.25 per share. The Company has determined that this is conventional convertible
debt, with a BCF. See Note 6(C).
During July 2012, a third party investor
advanced $12,000. The loan bears interest at 4%, is unsecured and due on demand.
During August, 2012, the Company received a demand from a former related party to repay $70,000 of convertible debt. The
Company is in default.
As of August 31, 2012, the Company owes
$2,805 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
(C) Debt Discount
At August 31, 2012 and November 30, 2011,
the Company recorded gross debt discounts of $120,000 and $30,000, respectively.
As a component of the computation for BCF,
the Company’s market price was determined based upon the quoted trading price (once publicly traded in February 2012) or
based upon recent third party cash offerings at the date of issuance (prior to February 2012).
At August 31, 2012, the Company had
fully amortized $120,000 in debt discount.
The following is a summary of the Company’s
convertible debt at August 31, 2012 and November 30, 2011.
|
|
2012
|
|
|
2011
|
|
Convertible Debt
|
|
$
|
120,000
|
|
|
$
|
30,000
|
|
Debt Discount
|
|
|
(120,000
|
)
|
|
|
(30,000
|
)
|
Amortization of Debt Discount
|
|
|
120,000
|
|
|
|
3,571
|
|
Convertible Debt – Net
|
|
$
|
120,000
|
|
|
$
|
3,571
|
|
Amortization expense for the nine months ended August 31, 2012 and 2011 was $116,429 and $0, respectively.
Note 7 Stockholders’ Deficit
On September 13, 2010, the Company issued
10,000 shares of common stock to its founders for $1 ($0.0001/share). On January 5, 2011, in connection with the re-domiciling
to Nevada, these shares were cancelled for no consideration.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
On January 28, 2011, the Company issued
one share of Series A, preferred stock for $1. This series of preferred stock had a provision that the holder of the one share,
a related party controlled by the Company’s Chief Executive Officer and a Director, can vote 50.1% of the total votes. There
are no preferences, dividends, or conversion rights.
In 2011, the Company issued the following
shares for cash and services:
Type
|
|
Quantity
|
|
|
Valuation
|
|
|
Range of Value per share
|
|
Cash
|
|
|
40,330,000
|
|
|
$
|
318,910
|
|
|
$
|
0.0001 – 0.50
|
|
Cash – related parties
|
|
|
44,800,000
|
|
|
|
4,480
|
|
|
$
|
0.0001
|
|
License agreement (1)
|
|
|
1,000,000
|
|
|
|
250,000
|
|
|
$
|
0.25
|
|
Services rendered (2)
|
|
|
4,150,000
|
|
|
|
50,000
|
|
|
$
|
0.012
|
|
Total
|
|
|
90,280,000
|
|
|
$
|
623,390
|
|
|
$
|
0.0001 - $0.50
|
|
During the nine months ended August 31,
2012, the Company issued the following shares for cash and services:
Type
|
|
Quantity
|
|
|
Valuation
|
|
|
Range of Value per share
|
|
Cash
|
|
|
200,000
|
|
|
$
|
50,200
|
|
|
$
|
0.25
|
|
Services rendered – related parties
|
|
|
50,000
|
|
|
|
11,000
|
|
|
$
|
0.22
|
|
Services rendered
|
|
|
150,000
|
|
|
|
97,500
|
|
|
$
|
0.65
|
|
Total
|
|
|
400,000
|
|
|
$
|
158,700
|
|
|
$
|
0.22-0.65
|
|
(1) See Note 7(C)
(2) In connection with the stock issued
for services rendered, the Company determined fair value based upon the value of the services provided, which was the most readily
available evidence.
(C) Stock issued for license
In connection with the license agreement
above, the following occurred:
On January 27, 2011, an agreement was executed
with Green Oil Plantations Ltd. and their affiliates (“Green Oil”) for an exclusive license of fifty years in exchange
for 1,000,000 shares of common stock, having a fair value of $250,000 ($0.25/share), based upon recent cash offerings to third
parties, at that time, to utilize Green Oil’s licensed technologies and turnkey model for growing energy crops in North America,
South America, Central America and the Caribbean excluding Cuba.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
The Company has agreed to pay a royalty
fee, as a percentage, of gross revenue as follows:
5% of the first $50,000,000 of gross revenue;
3% of the second $50,000,000 of gross revenue; and
1% of anything in excess of $100,000,000
If the Green Oil charges a lesser percentage
to another entity, then the first $50,000,000 will be decreased to the lowest percentage charged.
No such transactions have occurred as of
November 30, 2011 and through October 16, 2012.
As of August 31, 2012 and November 30,
2011 the license is summarized as follows:
|
|
2012
|
|
|
2011
|
|
License
|
|
$
|
250,000
|
|
|
$
|
250,000
|
|
Accumulated Amortization
|
|
|
(7,973
|
)
|
|
|
(4,205
|
)
|
License – Net
|
|
$
|
242,027
|
|
|
|
245,795
|
|
Amortization expense for the fiscal years
is as follows:
Year Ending November 30,
|
|
Amount
|
|
2012 (remaining 3 months)
|
|
$
|
1,229
|
|
2013
|
|
|
5,000
|
|
2014
|
|
|
5,000
|
|
2015
|
|
|
5,000
|
|
2016
|
|
|
5,000
|
|
Thereafter
|
|
|
220,798
|
|
Total
|
|
$
|
242,027
|
|
(D) Warrants
On January 11, 2011, the Company issued
1-year warrants for 1,000,000 shares with a consultant, with an exercise price of $1 per share. The warrants were granted for services
rendered. The warrants had a fair value of $60,800, based upon the Black-Scholes option-pricing model. The Company used the following
weighted average assumptions:
Expected dividends
|
|
|
0
|
%
|
Expected volatility
|
|
|
150
|
%
|
Expected term
|
|
|
1 year
|
|
Risk free interest rate
|
|
|
0.28
|
%
|
Expected forfeitures
|
|
|
0
|
%
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Remaining
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Contractual
|
|
|
|
|
|
|
|
|
|
Exercise
|
|
|
Life in
|
|
|
Intrinsic
|
|
|
|
Warrants
|
|
|
Price
|
|
|
Years
|
|
|
Value
|
|
Balance - November 30, 2011
|
|
|
1,000,000
|
|
|
$
|
1.00
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Forfeited/Cancelled(1)
|
|
|
(1,000,000
|
)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Balance – August 31, 2012 – outstanding
|
|
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
-
|
|
Balance – August 31, 2012 – exercisable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
(1)
|
On January 11, 2012, the 1,000,000 warrants expired unexercised.
|
Note 8 Related Party Transactions
License Agreement – Former Affiliate
of Chief Executive Officer
On November 30, 2010, the Company entered
into an exclusive license agreement with a company that is a former affiliate of the Company’s Chief Executive Officer. The
license gives the Company the right to utilize Intellectual Property rights (“IP”) and technology licenses to produce
high-density short rotation biomass energy crops on an exclusive basis in the United States, Central America, Mexico, and Guam
in perpetuity.
If the former affiliate company charges
a lesser percentage to another entity, then the first $50,000,000 will be decreased to the lowest percentage charged.
Note 9 Formation of Subsidiaries
On January 14, 2011, the Company formed
Global Energy Crops Corporation (“GECC”), a 100% wholly owned subsidiary. GECC intends to:
|
-
|
Seek financing from US aid and similar organizations for energy crop growing projects in third
world countries for the conversion to electricity and biofuels,
|
|
-
|
Joint venture with both international and smaller technology companies who are currently producing
electricity and biofuels wherein GECC intends to provide biomass feedstock, and
|
|
-
|
Execute supply chain contracts with major buyers of energy crop products including electricity
and biofuels.
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
On January 27, 2011, the Company formed
Green Oil Plantations Americas, Inc. (“Green Oil”), a 100% wholly owned subsidiary as the operating company for the
exclusive license agreement with Green Oil Plantations, Ltd. (See Note 7(C)).
All of the above subsidiaries are currently
inactive except for their formation.
Note 10 Commitments and Contingencies
Commitments
(A) Employment Agreements – Officers
and Directors
As of August 31, 2012, the Company had
employment agreements with certain officers and directors (two individuals) containing the following provisions:
Term of contract
|
5 years
|
Salary
|
$125,000 and $200,000
|
Salary deferral
|
All salaries will be accrued until the Company has raised $2,500,000.
|
(B) Lease Agreement
On March 18, 2011, the Company
entered into a 26-month lease that commenced on April 1, 2011 and will expire on May 31, 2013. The Company’s monthly
lease payment of $4,150 commenced on July 1, 2011. The Company will amortizes rent expense on a straight-line basis
over the occupancy period.
Rent expense was $33,043 and $18,357 for
the nine months ended August 31, 2012 and 2011, respectively.
Deferred
rent payable (component of accounts payable and accrued expenses) at August 31, 2012 and November 30, 2011 was $4,310 and $8,620,
respectively. Deferred rent payable is the sum of the difference between the monthly rent payment and the monthly rent expense
of an operating lease that contains escalated payments in future periods.
(C) Consulting Agreements
On January 5, 2012, the Company entered
into a consulting agreement for financing. The Company paid a retainer fee of $15,000 by issuing 60,000 shares of restricted common
stock at $0.25 per share. The fair value of the Company’s common stock was based upon third party cash offerings at that
time. The Company expensed this issuance as a component of general and administrative expenses.
As
of May 18, 2012, the Company rescinded the agreement, the expense was reversed and the shares were cancelled.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
On March 26, 2012, the Company entered
into a consulting agreement. The Company paid a fee of 150,000 shares of common stock, having a fair value of $97,500 ($0.65/share),
based upon the quoted closing trading price. During the nine months ended August 31, 2012, the Company expensed this issuance as
a component of general and administrative expenses.
Contingencies
From time to time, the Company may become
involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject
to inherent uncertainties, and an adverse result in these or other matters may arise that may harm its business. The Company is
currently not aware of any such legal proceedings or claims that they believe will have, individually or in the aggregate, a material
adverse effect on its business, financial condition or operating results.
Note 11 Revenue - other
On February 13, 2012, the Company was engaged
by a third party to provide consulting services; The Company will earn fees in the form of cash or common stock of the third party, a public company, at the discretion of the third
party, as follows:
● $120,000 was earned upon
execution of agreement (this amount has been received in the form of 15,000,000 shares ($0.008/share). The quantity of shares
issued was determined based upon a formula that would require a discount to market calculation to be performed by the public
entity. The Company recorded the quantity of shares received as revenues, with a corresponding asset classified as
available for sale securities. The fair value of the shares received upon the execution of this agreement was $253,500, as
evidenced by the quoted closing trading price.
● $60,000 is due on February 13,
2013; and
● $60,000 is due on February 13,
2014
Fees are payable in the form of cash or
common stock of the third party, a public company, at their discretion.
See Note 2 for reconciliation of amounts
associated with the purchase and sale of certain AFS securities.
Note 12 Fair Value of Financial Assets
and Liabilities
The Company measures assets and liabilities
at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents
the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction
between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset
or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value
on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The
following are the hierarchical levels of inputs to measure fair value:
• Level
1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
• Level
2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets
or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs
that are derived principally from or corroborated by observable market data by correlation or other means.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
August 31, 2012
Unaudited
• Level
3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value.
These assumptions are required to be consistent with market participant assumptions that are reasonably available.
The Company has assets measured at fair
market value on a recurring basis. Consequently, the Company had gains and losses reported in the statement of comprehensive income
(loss), that were attributable to the change in unrealized gains or losses relating to those assets and liabilities still held
at the reporting date for the period ended August 31, 2012.
The following is the Company’s assets
measured at fair value at August 31, 2012 and November 30, 2011:
|
|
August 31, 2012
|
|
|
November 30, 2011
|
|
Level 1 – None
|
|
$
|
-
|
|
|
$
|
-
|
|
Level 2 – Marketable Securities (AFS)
|
|
|
74,128
|
|
|
|
-
|
|
Level 3 – None
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
$
|
74,128
|
|
|
$
|
-
|
|
The carrying amounts reported in the balance
sheet for available for sale securities, prepaid expenses, accounts payable and accrued expenses, accounts payable and accrued
expenses – related parties, notes payable, notes payable – related parties, convertible debt and convertible debt –
related party, approximate fair value based on the short-term nature of these instruments.
Note 13 Subsequent Events
In September 2012, the Company repaid
an advance of $1,200 to its Chief Executive Officer.
ITEM 2. MANAGEMENT'S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
SPECIAL NOTE OF CAUTION REGARDING FORWARD-LOOKING
STATEMENTS
Statements made in this 10-Q that are
not historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section
27A of the of the Securities Act of 1933 (the “Act”) and Section 21E of the Securities Exchange Act of 1934. In some cases,
you can identify forward-looking statements by terminology such as "may", "should",
"intends", "expects", "plans", "anticipates", "believes", "estimates",
"predicts", "potential", or "continue" or the negative
of these terms or other comparable terminology. We intend that
such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not
to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking
statements represent management’s best judgment as to what may occur in the future. However, forward-looking
statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events
to differ materially from historical results of operations and events and those presently anticipated or projected. We
disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date
of such statement or to reflect the occurrence of anticipated or unanticipated events.
Unless the context otherwise requires,
The "Company", "we," "us," and "our," refer to (i) BioPower Operations Corporation.; (ii)
BioPower Corporation (“BC”), (iii) Green Oil Plantations Americas, Inc. (“GOP”), and (iv)
Global Energy
Crops Corporation
(GECC) .
Overview
BioPower Corporation was incorporated
September 13, 2010, in the State of Florida and re-domiciled as BioPower Operations Corporation which was incorporated in the
State of Nevada on January 5, 2011.
We are a development stage company and
have not yet generated or realized any revenues from business operations. Our auditors have issued a going concern opinion. This
means there is substantial doubt that we can continue as an on-going business for the next twelve (12) months unless we obtain
additional capital to pay our bills. This is because we have not generated minimal revenues from a consulting agreement and minimal
revenues are anticipated until we begin marketing our products to customers. Accordingly, we must raise cash from sources other
than revenues generated such as from the proceeds of loans, sale of common shares, advances from related parties and consulting
agreements.
From inception (September 13, 2010) to
August 31, 2012, the company's business operations have primarily been focused on developing our business plan, developing potential
products and biomass projects, becoming a trading public company through an S-1 registration statement, raising money and developing
on-line exchanges.
Castor Project
The Company has begun the process to
obtain financing for a castor plantation and milling operation to supply castor oil to the U.S.A. and/or international
marketplace. We have identified a hybrid seed that we believe may result in high yields per acre. We have identified unique
growing protocols that also may enhance the yield of seed thus oil by weight. We have identified engineering firms to prepare
both general and site specific engineering for permitting and construction purposes. We have identified the mill equipment to
process the seed into oil and the agricultural equipment required to facilitate the growing protocols that have been
identified. We are currently working on the development of a long-term (greater than one year) purchase agreement for the
sale of castor oil. Although we have discussed various potential sites in the center of Florida, we have not made a final
determination of the specific location.
The U.S.A. currently imports almost 100%
of the castor oil used as a feedstock into the personal care, pharmaceuticals, polymers and plastics, adhesives, coatings and
other specialty chemical markets. The Company proposes to develop a project in Florida to grow proven hybrid castor which can
be harvested within 110 days per crop. Given the rainfall, the temperature profile and the nature of the soil, it is anticipated
that the land when developed will produce 2.6 to 3.0 metric tons of oil seeds per acre based on two crops per year. We will process
the seeds into oil (43% of seed weight) with our own, vertically integrated mill which we consider critical to this project. Based
on our ability to obtain financing in this fiscal year, we hope to realize revenues and profits from this operation in 2013.
There can be no assurance the above Castor
Project will ever be achieved.
Potential Business Opportunities
Our experienced management team has been
reviewing and doing due diligence for biomass products, biofuels production and processes that we believe will provide revenue
and profitability for the Company. We may license or acquire such opportunities after we review such opportunities to determine
if they meet our potential goals and criteria.
There can be no assurance that the Company will ever
successfully commence any of the above.
FTZ Exchange, LLC
On June 8, 2012, the Company’s Chief
Executive Officer contributed 100% of his member interest in FTZ Exchange, LLC, (“FTZ”) a 100% wholly owned subsidiary,
to the Company for no consideration. FTZ is a licensing company that licenses business know-how and technology to build transaction
fee based exchanges for the sale of products and services in vertical markets.
FTZ combines on-line
and off-line commercial trade strategies with transaction fee based revenue models to create internet exchanges to sell or source
products and services to business to business (B2B), business to consumer (B2C) and in some instances (B2B2C) business to business
and business to consumer. FTZ exchanges also include government communities.
Health Exchange
FTZ has been in the development stage of a health exchange
since January 2012. FTZ currently owns 50% of the Qx Health Exchange with Quture, Inc. (“QUTR”). This exchange
is for the sale of health products and services for the communities of health product manufacturers, insurance companies, hospitals,
physicians, healthcare providers, medical tourism and patients.
Quture and FTZ have been working jointly to develop the exchange
in conjunction with Quture joint venture partners for the backbone. The initial phase requires no investment from Quture or FTZ
until the system is proven. Quture and FTZ are in discussions with investors to fund the operations and build out of the exchange.
There can be no assurance such funding will ever be achieved or that the Qx Health Exchange will ever be launched.
Capacity Exchange
FTZ has executed a Strategic Alliance with Capacity 360, LLC
and Founder Tom Settineri to develop excess capacity transactions through off-line in-house associates. Capacity 360, LLC is a
company that assists Global 2000 corporations and other corporations to develop excess capacity strategies to optimize and monetize
their unused, under-utilized manufacturing capacities and assets, with the goal of meeting each corporation's strategic goals.
Capacity 360's business model increases a corporate return on investment by utilizing excess capacity and realizing economies
of scale combined with the development of new channels of distribution for the corporation's products, services and assets. Capacity
360’s business model also addresses excess inventories.
The exchange is not necessary for Capacity 360 to generate
revenues. FTZ is working with Capacity 360 to develop an on-line exchange which both believe would enhance the transactions and
activities of Capacity 360’s business and provide for a faster reach into global business development.
Capacity 360 and FTZ will seek investors for the capacity exchange. There can be no assurance such funding will ever be achieved
or that the capacity exchange will ever be launched.
FTZ Energy Exchange Corporation
FTZ formed FTZ Energy Exchange Corporation on May
14, 2012 as a wholly-owned subsidiary to launch an energy exchange. FTZ will require funding to launch an energy exchange.
There can be no assurance such funding will ever be achieved or that the energy exchange will ever
be launched.
RESULTS OF OPERATIONS
Our financial statements have been prepared
assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability
and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.
We expect that we will require additional capital to meet our operating requirements. We expect to raise additional capital through,
among other things, the sale of equity or debt securities.
Three Months Ended August 31, 2012 Compared to the
Three Months Ended August 31, 2011
The following analysis reflects the condensed
consolidated results of operations of BioPower Operations Corporation and its subsidiaries.
Consolidated Statement of Income
|
|
|
Three Months Ended
|
|
|
|
|
|
|
August 31,
|
|
|
Increase
|
|
(Dollars)
|
|
2012
|
|
|
2011
|
|
|
(Decrease)
|
|
Net Sales
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
General and administrative expenses
|
|
$
|
245,134
|
|
|
$
|
269,055
|
|
|
$
|
(23,921
|
)
|
Depreciation and amortization
|
|
|
2,656
|
|
|
|
2,656
|
|
|
|
0
|
|
Interest expense
|
|
|
34,889
|
|
|
|
0
|
|
|
|
34,889
|
|
Loss on sale of available-for-sale marketable securities
|
|
|
29,838
|
|
|
|
0
|
|
|
|
29,838
|
|
Net loss
|
|
$
|
(312,517
|
)
|
|
$
|
(271,711
|
)
|
|
$
|
40,806
|
|
The following analysis reflects the condensed
consolidated results of operations of BioPower Operations Corporation and its subsidiaries.
Neither
Net Sales
nor
Cost
of Sales
was realized
during either three month period
.
There is no
Net Sales
nor
Cost of Sales
as operations have not commenced.
Operating Expenses and Depreciation.
Operating
expenses and depreciation for the three month period ended August 31, 2012 of $247,790 decreased $23,921 (9%) as compared with
$271,711 for the three month comparable period ended in 2011.
b
elow details the
components of operating expense, as well as the dollar and percentage changes for the three-month period ended August 31.
General and administrative expenses primarily consist of development
costs, corporate overhead, accrued payroll and payroll taxes, financial and administrative contracted services for professional
fees including legal and accounting, SEC filing fees, insurance and stock based compensation.
Wage and wage related costs which include
salaries, commissions, taxes and benefits, decreased $17,068(11%), due to Mr. Shepherd resigning as President during the quarter
and three months compensation for an executive assistant compared with 2011 which includes three months compensation for Ms. Nelson
and Messrs. Kohn and Shepherd and two months’ compensation for an executive assistant.
Professional fees include legal, accounting,
stock transfer agent, SEC filing, and general consulting fees. Professional fees increased for the three months ended August 31,
2012 versus the same period last year by $20,765 for an increase of 52% primarily resulting from a significant increase in consulting
fees incurred in conjunction with the engagement of investment banking firms for fund raising which were paid in restricted common
stock at fair market value.
Insurance costs for the three months ended
August 31, 2012, were $16,320 compared to $4,040 for the same period in 2011, an increase of $12,280 (3,040%) attributable to
the cost of directors’ and officers’ liability insurance in 2012 which was not in effect in 2011.
Rent was $11,014 for the three months ended
August 31, 2012, as compared to $11,014 for the same period in 2011, for the Company’s corporate office rental which commenced
in April 2011 and terminates in May 2013.
Travel expense for the three months ended
August 31, 2012 of $12,823 as compared with the same period for 2011 of $37,676 for a decrease of $24,853 (66%) is a result of
international travel associated with our licensed technologies in 2011 that was not repeated during the same period of 2012 and
less travel related to business development activities in 2012.
Miscellaneous expense decreased by $14,795
(61%) to $9,528 for the three months ended August 31, 2012, as compared to $24,323 for the same period in 2011. The decrease is
attributable to a mix of increasing and decreases expenses that are not material in aggregate.
Depreciation and amortization expense remained
the same at $2,656 for the three months ended August 31, 2012 as compared with $2,656 for the same period of 2011 as a result
of no changes to depreciable or amortizable assets.
Interest Expense
increased
significantly from $0 in 2011 as compared with $34,889 for the three month period in 2012. This is attributable to the debt discount
on the convertible note for the $70,000 loan to the Company from the former President, Dale Shepherd.
Net Loss and Net Loss per Share.
Net Loss for the three months ended August 31, 2012 was $312,517 as compared with $271,711 for the same period in 2011,
for an increase in net loss of $40,806 (15%). The increased net loss for the three months ended August 31, 2012 as compared with
the same period in 2011 arose primarily from (i) increased professional fees of $20,765 and (ii) increased insurance costs of
$12,280. In addition there were loans to the company in the comparable 2012 period with discounting treatment that resulted in
an increase in recorded interest cost of $34,889.
Nine Months Ended August 31, 2012 compared to the
Nine Months Ended August 31, 2011
The following analysis reflects the condensed
consolidated results of operations of BioPower Operations Corporation and its subsidiaries.
Consolidated Statement of income
|
|
Nine Months Ended
|
|
|
|
|
|
|
August 31,
|
|
|
Increase
|
|
(Dollars)
|
|
2012
|
|
|
2011
|
|
|
(Decrease)
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales
|
|
$
|
253,500
|
|
|
$
|
0
|
|
|
$
|
253,500
|
|
General and administrative expenses
|
|
$
|
792,701
|
|
|
$
|
740,620
|
|
|
$
|
52,081
|
|
Depreciation and amortization
|
|
|
7,940
|
|
|
|
5,068
|
|
|
|
2,872
|
|
Interest expense
|
|
|
119,619
|
|
|
|
0
|
|
|
|
119,619
|
|
Loss on sale of available-for-sale marketable securities
|
|
|
29,838
|
|
|
|
0
|
|
|
|
29,838
|
|
Net loss
|
|
$
|
(696,598
|
)
|
|
|
(745,688
|
)
|
|
|
(49,090
|
)
|
Net Revenues.
Net revenues were $253,500 for
the nine month period ended August 31, 2012 compared to $0 for the nine month comparable period in 2011 for an increase of $253,500.
This increase was due to a non-core business consulting agreement paid in stock and valued at the date of agreement during the
December to February quarter.
Operating Expenses and Depreciation.
Operating
expenses and depreciation for the three month period ended August 31, 2012 of $561,273 increased $90,055 (19%) as compared with
$471,218 for the three month comparable period ended in 2011. The table below details the components of operating expense, as
well as the dollar and percentage changes for the nine month period ended August 31st.
General and administrative expenses primarily consist of development
costs, corporate overhead, accrued payroll and payroll taxes, financial and administrative contracted services for professional
fees including legal and accounting, SEC filing fees, insurance and stock based compensation.
Wage and wage related costs which include
salaries, commissions, taxes and benefits, increased $66,516 (17%), inasmuch as nine months 2012 includes nine month’s compensation
for Ms. Nelson and Messrs. Kohn and Shepherd and an executive assistant as compared to nine months ended August 31, 2011 which
includes nine months compensation for Ms. Nelson and Mr. Kohn, eight months’ compensation for Mr. Shepherd and five months
compensation for an executive assistant.
Professional fees include legal, accounting,
stock transfer agent, SEC filing, and general consulting fees. Professional fees decreased for the three months ended August 31,
2012 versus the same period last year by $37,762, a decrease of 16% primarily resulting from a significant decrease in legal and
accounting fees incurred in conjunction with the S-1 filing in 2011 offset partially by increased fundraising costs for the engagement
of investment banking firms in the June through August period of 2012.
Insurance costs in the nine months ended
August 31, 2012, were $48,263 compared to $4,443 for the same period in 2011, an increase of $43,820 (986%). The increase is attributed
primarily to directors’ and officers’ liability insurance (D&O) being bound effective August 2011 with no such
D&O cost in the comparable 2011 period.
Rent was $33,043 through August 31, 2012
(nine months’ rental cost) an increase of $14,431 (78%) as compared with $18,612 for the nine months ended August 31, 2011(five
months’ rental cost) due to the Company’s corporate office rental commencing in April 2011.
Travel expense for the nine months ended
August 31, 2012 of $45,021 as compared to the same period for 2011 of $48,115, or a decrease of $3,094 (6%) is a result international
travel associated with our licensed technologies in 2011 that was not repeated during the same period of 2012.
Miscellaneous expense decreased by $30,445
(50%) to $30,031 for the nine months ended August 31, 2012, as compared with $60,477 for the same period in 2011. The decrease
is attributable to a mix of increasing and decreases expenses that are not material by nature.
Depreciation and amortization expense in
our operating expenses for the nine months ended August 31, 2012 of $7,940 increased 57% compared to $5,068 for the same period
for 2011 as a result primarily due to the timing of the acquisition of assets during the start-up phase of the business.
Interest Expense
for the
nine months ended August 31, 2012 was $119,619 as compared with interest expense of $0 for the same period last year. The increase
in interest expense is primarily the result of debt discount on the convertible note for the $70,000 loan to the Company from
the former President, Dale Shepherd.
Net loss
for the nine months
ended August 31, 2012 was $696,598 as compared with $745,688 for the same period in 2011, for a decreased net loss of $49,090
(7%). The decreased net loss for the nine months ended August 31, 2012 compared to the same period in 2011 arose primarily from
the consulting revenue of $253,500 realized in the December to February quarter of 2012 and reduced professional fees of $37,762
offset partially by (i) increased wage and wage related costs of $66,516, (ii) increased interest costs of $119,619, (iii) increased
insurance costs of $43,820 and (iv) increased rent costs of $14,431.
Liquidity and Financial Condition
|
|
Nine Months Ended
|
|
|
|
August 31
|
|
|
August 31
|
|
Category
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
$
|
(207,556
|
)
|
|
$
|
(262,362
|
)
|
Net cash provided (used) in investing activities
|
|
|
11,330
|
|
|
|
(29,294
|
)
|
Net cash provided by financing activities
|
|
|
194,292
|
|
|
|
302,463
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash
|
|
$
|
(1,934
|
)
|
|
$
|
10,807
|
|
Cash Flows from Operating Activities
Net cash used by operating
activities was $207,556 for the nine month period ended August 31, 2012 as compared with net cash used of $262,362 for the comparable
period in 2011 resulting in an increase in cash provided of $54,806. The increase in the cash provided from operating activities
is due to favorable items including a decrease in a net loss of $49,090, an increase in amortization and depreciation of $809,
an increase in stock issued for services of $58,500, an increase in amortization of debt discount $116,429, a decrease in warrants
issued for services of $60,800, and an increase in accounts payable and accrued liabilities to related parties of $433,788 offset
partially by unfavorable items including a decrease in accounts payable and accrued liabilities of $35,163 and a decrease in
prepaid expenses of $267.
Cash Flows Used in Investing Activities
Net cash provided
by investing activities was $11,330 for the nine months ended August 31, 2012 as compared to net cash used in investing activities
of $29,294 for the comparable period in 2011. The only investing activity in 2012 was due to the proceeds from the sale of available-for-sale
marketable securities of $11,330 received by the Company as opposed to the purchase of equipment in 2011.
Cash Flows from Financing Activities
We have financed our operations primarily
from either advancements or the issuance of equity and debt instruments. For the nine month period ended August 31, 2012 cash
flows provided by financing activities was $194,292 as compared to $302,463 for the comparable period in 2011. The decrease was
a result of less money being received from proceeds from the issuance of common stock and an increase in loans from related parties.
Management is seeking, and expects to continue to seek to raise additional capital through equity or debt financings, including
through one or more equity or debt financings to fund its operations, and pay amounts due to its creditors and employees. However,
there can be no assurance that the Company will be able to raise such additional equity or debt financing or obtain such bank
borrowings on terms satisfactory to the Company or at all.
As of August 31, 2012, our company had a working capital deficit
of approximately $1,115,728.
Cash and Cash Equivalents
Our cash and cash equivalents decreased
during the nine months ended August 31, 2012 by $1,934, compared to an increase in cash and cash equivalents during the same period
in 2011 of $10,807.
Working Capital Information
-
The following
table presents a summary of our working capital at the end of each period:
|
|
(Unaudited)
|
|
|
|
|
Category
|
|
August 31, 2012
|
|
|
November 30, 2011
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
4,177
|
|
|
$
|
6,111
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
84,392
|
|
|
|
12,465
|
|
Current liabilities
|
|
|
1,200,120
|
|
|
|
550,031
|
|
Working capital (deficit)
|
|
$
|
(1,115,728
|
)
|
|
$
|
(537,566
|
)
|
Nine Month Period Ended August 31,
2012
At August 31, 2012,
we had a working capital deficit of $1,115,728 compared with a working capital deficit at November 30, 2011 of $537,566 or an
increase in working capital deficit of $578,162 (108%). As of August 31, 2012, we had cash equivalents of $4,177 as compared to
$6,111 on November 30, 2011. The decrease in cash is the net result of our operating, investing and financing activities outlined
above.
As of August 31, 2012,
our current assets were $84,392 compared to $12,465 in current assets at November 30, 2011. Current assets were comprised of $4,177
in cash, $74,128 in available-for-sale marketable securities and $6,087 in prepaid expenses at August 31, 2012, and $6,111 in
cash and $6,354 in prepaid expenses at November 30, 2011. As at August 31, 2012, our current liabilities were $1,200,120 compared
to $550,031 at November 30, 2011. At August 31, 2012, our current liabilities were comprised of accounts payable and accrued expenses
of $133,555, accounts payable and accrued expenses related parties of $892,473, notes payable to related party of $42,092, notes
payable $12,000 and convertible debt of $120,000 as compared to November 30, 2011 with current liabilities comprised of $546,460
in accounts payable and accrued expenses and related party convertible debt of $3,571.
We are a development
stage company whose revenue generating activities have not produced sufficient funds for profitable operations, and we have incurred
operating losses since inception. Accordingly, we have continued to utilize the cash raised in our financing activities to fund
our operations. In addition to raising cash through additional financing activities, we may supplement our future working capital
needs through the extension of trade payables and increases in accrued expenses. In view of these matters, realization of certain
of the assets in the accompanying balance sheet is dependent upon our continued operations, which in turn is dependent upon our
ability to meet our financial requirements, raise additional financing, and the success of our future operations.
Additional Capital
To the extent that additional capital is
raised through the sale of our equity or equity-related securities of our subsidiaries, the issuance of our securities could result
in dilution to our stockholders. No assurance can be given that we will have access to the capital markets in the future, or that
financing will be available on terms acceptable to satisfy our cash requirements, implement our business strategies, If we are
unable to access the capital markets or obtain acceptable financing, our results of operations and financial condition could be
materially and adversely affected. We may be required to raise substantial additional funds through other means. We have
not begun to receive revenues from our cord projects or services at this point. Management may seek to raise additional capital
through one or more equity or debt financings or through bank borrowings. We cannot assure our stockholders that our technology
and products will be commercially accepted or that revenues will be sufficient to fund our operations.
If adequate funds are not available to
us, we may be required to curtail operations significantly or to obtain funds through entering into arrangements with collaborative
partners or others that may require us to relinquish rights to certain of our potential projects or products.
PLAN OF OPERATION AND FUNDING
Since inception (September 13, 2010) to
August 31, 2012, the Company has spent a total of $527,076 on the start-up, development and administrative costs. We have not
yet generated any revenue from business operations.
Since inception (September 13, 2010),
the majority of the company's time has been spent refining its business plan, conducting industry research, developing potential
projects, licensing biomass opportunities, reviewing technologies, preparing an S-1and preparing for additional financing, funding
of operations and funding of projects.
The Company is a development stage company
focused on growing biomass crops coupled with processing and/or conversion facilities to produce oils, biofuels, electricity and
other biomass products.
BioPower is focused on a short term strategy
for growing a biomass crop that can be converted into bio oils, biofuels and steam. The Company has begun the process to obtain
financing for a castor plantation and milling operation to supply castor oil to the U.S.A. marketplace. We are currently in discussions
of a long-term (greater than one year) purchase agreement. The U.S.A. currently imports almost 100% of the castor oil used as
a feedstock into the personal care, pharmaceuticals, polymers and plastics, adhesives, coatings and other specialty chemical markets.
The Company proposes to develop a project in Florida to grow proven hybrid castor which can be harvested within 110-125 days per
crop. Given the rainfall, the temperature profile and the nature of the soil, it is anticipated that the land when developed will
produce 2.6 to 3.0 tons of oil seeds per acre based on two crops per year. We will process the seeds into oil (43% of seed weight)
with our own, vertically integrated mill which we consider critical to this project.
In addition, we have been in discussions
for a potential biomass project in South America.
Our experienced management team also continually
searches for biomass products and processes that we believe will provide short term revenue and profitability for the Company.
We review business plans and technologies to determine if they meet our potential short-term goals and criteria.
Biomass is all plant and animal matter
on the Earth's surface. Harvesting biomass such as crops, trees or dung and using it to generate energy such as heat, electricity
or motion, is bio energy. Biomass is a very broad term which is used to describe material of recent biological origin that can
be used either as a source of energy or for its chemical components. As such, it includes trees, crops, algae and other plants,
as well as agricultural and forest residues. It also includes many materials that are considered as wastes by our society including
food and drink manufacturing effluents, sludge, manures, industrial (organic) by-products and the organic fraction of household
waste.
Our long-term strategy is to develop our
core biomass projects yielding net cash flow from operations from the production of bio-oils, biofuels, fertilizer or other products.
FTZ Exchange LLC.
The FTZ Exchange, LLC is a licensing company
that licenses business know-how and technology to build transaction fee based exchanges for the sale of products and services
in vertical markets. FTZ’s first license is a joint venture to form the Qx Health Exchange with Quture, Inc. FTZ owns 50%
of the Qx Health Exchange. Our FTZ strategy is to build or license many exchanges in joint venture or to launch exchanges that
are 100% Company owned. We intend to launch an Energy Exchange which can sell energy related products and services globally. Some
of these products will include energy credits, as previously mentioned in our S-1, biofuels, bio-oils and commodities including
bio-jet fuel, oil, gas, electric and many other energy related products and services.
The Company intends to raise money for
the exchanges by selling stock in the exchanges versus selling common stock of BioPower so that we will not directly dilute the
Company’s shareholders. The Company believes that each exchange will establish its own value and therefore the dilution
for each exchange will be dictated by its value.
We intend to operate our Company through
many wholly-owned subsidiaries and special entity corporations and partnerships. FTZ Exchange, LLC, FTZ Energy Exchange Corporation,
BioPower Corporation, Global Energy Crops Corporation and Green Oil Plantations Americas Inc. are our main wholly-owned subsidiaries.
Other subsidiaries and special entity corporations and LLCs may be formed as required to operate the Company.
We estimate our maximum operating expenses
and working capital requirements for the next twelve month period to be as follows for BioPower Operations Corporation:
Business development costs for biomass operations
|
|
$
|
3,250,000
|
|
Management and Consulting
|
|
|
825,000
|
|
General and Administrative
|
|
|
925,000
|
|
Total
|
|
$
|
5,000,000
|
|
We anticipate that we will be required
to raise additional funds through private sales of debt or equity securities of our company, to fund our operations and execute
our business plan. There is no assurance that the financing will be completed on terms advantageous to us, or at all. If we are
not successful in raising additional funding, we may be forced to curtail or cease some of all of our operations and/or curtail
or elect not to proceed with certain aspects of our business plan.
We may also encounter unforeseen costs
that could also require us to seek additional capital. As a result, we will need to raise additional debt and/or equity
funding. However, no assurance can be given that we will be able to sell any of such securities. An inability
to obtain such funding would prevent us from developing any biomass feedstock plantations. Our ability to obtain additional
capital also will depend on market conditions, national and global economies and other factors beyond our control.
The terms of any future debt or equity funding that we may obtain may be unfavorable to us and to our stockholders.
If we are successful and we
are able to raise the entire $5,000,000, we will have sufficient funds to meet business development activity costs
for the current fiscal year, and we will be able to implement key
aspects of our business plan, including business development costs for our energy
growing operations. We would have a total of $1,700,000 remaining for working capital. We expect
these amounts will be sufficient to initiate and sustain our business development activities for one year.
Upon having been
successful in raising $2,500,000, the salary obligation to our CEO and Director of Business Strategy will
come into effect, and any amounts accrued to date, and monthly amounts going
forward, will be payable for a period up to one year including accruals. The initial annual amounts are $200,000
and $125,000 respectively.
The amount
and timing of additional funds that might be required cannot be definitively stated as at
the date of this report and will be dependent on a variety of factors, including the
success of our initial operations and the rate of future expansion that we might plan to
undertake. If we were to determine that additional funds are required, we would be required to raise
additional capital either by way of loans or equity, which, in the case of equity, would
be potentially dilutive to existing stockholders. The Company cannot be certain that we will be able to
raise any additional capital to fund our operations or expansion past the current fiscal year.
OUR CHALLENGES
Our ability to successfully operate our
business and achieve our goals and strategies is subject to numerous challenges and risks including for example:
|
·
|
any
failure to develop
our projects and
our inability to
sufficiently meet
our customers' demands
for our products;
|
|
·
|
any
inability to effectively
manage rapid growth;
|
|
·
|
risks
associated with
future joint ventures,
strategic alliances
or acquisitions;
|
|
·
|
economic,
political, regulatory,
legal and foreign
risks associated
with alternative
energy; and,
|
|
·
|
any
loss of key members
of our management.
|
OFF-BALANCE SHEET ARRANGEMENTS
As of the date of this Quarterly Report,
we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our
financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that are material to investors.
GOING CONCERN
The financial statements have been prepared "assuming that we will continue as a going concern,"
which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK.
This item is not applicable to smaller
reporting companies.
ITEM 4. CONTROLS AND PROCEDURES.
Our management is responsible for establishing
and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange
Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules
and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated
to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
An evaluation was conducted under the
supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls
and procedures as of August 31, 2012. Based on that evaluation, our management concluded that our disclosure controls and procedures
were effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under
the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such
officer also confirmed that there was no change in our internal control over financial reporting during the three-month period
ended August 31, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial
reporting.
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
Management is not aware of any legal proceedings contemplated
by any governmental authority or any other party involving us. As of the date of this Quarterly Report, no director or officer
is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management
is not aware of any other legal proceedings pending or that have been threatened against us.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE
OF PROCEEDS.
On January 5, 2012, the Company entered
into a non-exclusive agreement with Halcyon Cabot Partners, an investment banking firm, to act as our advisor to raise up to $5,000,000
in capital and $500,000 in the form of a Bridge Loan. The initial term of the agreement was four months. The Company agreed
to pay a retainer fee of $15,000, by issuing 60,000 shares of restricted common stock at $.25 per share. The shares issued are
exempt from registration under Sec. 4(2) of the Securities Act of 1933. The Company has notified Halcyon that they failed to provide
the services in the agreement and therefore the Company does not owe the 60,000 shares.
On February 22, 2012 a shareholder purchased
200,000 shares of restricted common stock at $.25 per share. The shares issued are exempt from registration under Sec. 4(2) of
the Securities Act of 1933.
On March 26, 2012 the Company entered
into an agreement with Tejas Securities Group, Inc. as its financial advisor in connection with a proposed offering and private
placement of investment capital of up to Twenty Million Dollars ($20,000,000) in the form of senior, junior, convertible or subordinated
debt, preferred equity or common equity financing for a Castor Project and in connection with the proposed offering and private
placement of investment capital of up to Five Million dollars ($5,000,000) in the form of common stock, at the corporate holding
company level.
The Company agreed to pay a retainer fee
of $60,000, by issuing 150,000 shares of restricted common stock at $.40 per share. The shares issued are exempt from registration
under Sec. 4(2) of the Securities Act of 1933.
On June 7, 2012, the Company issued 50,000
shares of common stock to the Chairman of the Audit Committee for services rendered, having a fair value of $11,000 ($0.22/share),
based upon the quoted closing trading price. The shares issued are exempt from registration under Sec. 4(2) of the Securities
Act of 1933.
On June 7, 2012, the Company issued 10,000
shares of common stock to a consultant for services rendered in locating appropriate land for a castor project in Florida, having
a fair value of $2,200 ($0.22/share), based upon the quoted closing trading price. The shares issued are exempt from registration
under Sec. 4(2) of the Securities Act of 1933.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
No report required.
ITEM 4. MINE SAFETY DISCLOSURES
No report required.
ITEM 5. OTHER INFORMATION.
No report required.
Item 6. Exhibits.
The following exhibits are being filed as part of this Quarterly
Report on Form 10-Q.
Exhibit
|
|
|
Number
|
|
Exhibit Description
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
|
|
|
|
101
|
|
Interactive data files pursuant to Rule 405 of Regulation S-T.*
|
* Furnished herewith. XBRL (Extensible Business Reporting
Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections
11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and otherwise is not subject to liability under these sections.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 22, 2012
|
BioPower Operations Corporation
|
|
|
|
By:
|
/s/ Robert D. Kohn
|
|
|
Robert D. Kohn, Chief Executive Officer, Principal Executive
Officer and Director
|
Grafico Azioni BioPower Operations (CE) (USOTC:BOPO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni BioPower Operations (CE) (USOTC:BOPO)
Storico
Da Giu 2023 a Giu 2024